Predictive Oncology Inc.’s (NASDAQ: POAI) Exclusive Resources Provide Personal Profiling, Tools to Improve Patient Outcomes
POAI, Helomics builds AI-driven models that predict drug response, patient outcome Company tests patient tumor, generates comprehensive picture that oncologists use to individualize therapy Key to individualized insight is POAI’s Tumor Drug Response Profiling (“TDRP”) platform, NGS-based genomic profiling, unmatched cancer knowledge base Guided by the mantra that “cancer is personal — we believe therapy should be too,” Predictive Oncology (NASDAQ: POAI) subsidiary Helomics focus on building AI-driven models that will predict drug response and patient outcome of individual tumors. With the largest tumor inventory in the world, POAI leads the way in providing a functional precision medicine approach that harnesses…